Bodey B, Taylor C R, Siegel S E, Kaiser H E
Department of Pathology, School of Medicine, University of Southern California, Los Angeles 90033, USA.
Anticancer Res. 1995 Nov-Dec;15(6B):2461-8.
Resistance to several cytotoxic agents (MultiDrug Resistance MDR), including anthracyclines, vinca alkaloids and epipodophylline derivatives can occur in human osteosarcoma (OS) cells, detected by the overexpression of a 170 kD glycoprotein (p170), as a result of increased expression of the MDR gene (mdr1). The p170 glycoprotein in normal cells is a membrane transport system protein and its quantitative increase results in increased drug efflux and decreased intracellular drug concentration. Normal renal epithelial cells express p170 as a function of their secretory duties therefore this human tissue was used as a positive tissue control in our immunocytochemical study. This partially retrospective immunocytochemical study was carried out on routine, 10% neutral formalin fixed, decalcified, paraffin embedded, tissue sections of 43 OSs, treated between 1981 and 1993 at the Orthopaedic Hospital of Los Angeles. The immunoperoxidase antigen detection protocol, submitted by Hsu et al (1981) was employed. The search for p170 was carried out with three newly developed monoclonal antibodies (MoABs) (JSB-I, C-219 and C-494, from Signet Laboratories, Dedham, MA 02026). The initial expression of MDR was not detectable in seven OSs. 36/43 OSs expressed p170 on/in their cells. Heterogenous cellular microenvironment and various grades of differentiation features were also determined in the examined OSs. In 17/43 OS cases presence of intensive staining (probably overexpression) of p170 protein was registered. The 43 OSs exhibited different staining patterns with each MoAB. MoAB JSB-I reacted with a transmembranic antigen epitope. The long incubation time with C-219 resulted in heterogeneous cytoplasmic staining. MoAB C-494 also produced an intensive staining mainly localized on the cell membrane of the OS cells. These statistically significant immunocytochemical results suggest a direct correlation between the quantitative presence of p170 glycoprotein in human OS cells and the efficacy of the employed chemotherapy. Future observations employing the in situ hybridization technique will allow the quantitative measurement of the primary or secondary presence of MDR glycoprotein in human OS cells.
在人类骨肉瘤(OS)细胞中,可能会出现对几种细胞毒性药物的耐药性(多药耐药,MDR),包括蒽环类药物、长春花生物碱和表鬼臼毒素衍生物,这可通过一种170 kD糖蛋白(p170)的过表达检测到,这是MDR基因(mdr1)表达增加的结果。正常细胞中的p170糖蛋白是一种膜转运系统蛋白,其数量增加会导致药物外排增加和细胞内药物浓度降低。正常肾上皮细胞根据其分泌功能表达p170,因此在我们的免疫细胞化学研究中,这种人体组织被用作阳性组织对照。这项部分回顾性免疫细胞化学研究是对1981年至1993年期间在洛杉矶骨科医院接受治疗的43例骨肉瘤的常规、10%中性福尔马林固定、脱钙、石蜡包埋组织切片进行的。采用了Hsu等人(1981年)提交的免疫过氧化物酶抗原检测方案。使用三种新开发的单克隆抗体(MoABs)(JSB-I、C-219和C-494,来自Signet Laboratories,马萨诸塞州德达姆02026)检测p170。在7例骨肉瘤中未检测到MDR的初始表达。43例骨肉瘤中有36例在其细胞上/细胞内表达p170。在所检查的骨肉瘤中还确定了异质性细胞微环境和不同程度的分化特征。在43例骨肉瘤病例中的17例中,记录到p170蛋白存在强烈染色(可能是过表达)。43例骨肉瘤与每种单克隆抗体呈现出不同染色模式。单克隆抗体JSB-I与一种跨膜抗原表位发生反应。与C-219长时间孵育导致异质性细胞质染色。单克隆抗体C-494也产生主要定位于骨肉瘤细胞膜上的强烈染色。这些具有统计学意义的免疫细胞化学结果表明,人类骨肉瘤细胞中p170糖蛋白的定量存在与所采用化疗的疗效之间存在直接相关性。未来采用原位杂交技术的观察将能够定量测量人类骨肉瘤细胞中MDR糖蛋白的原发性或继发性存在情况。